BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

Indianapolis is “potentially interested in acquiring” the right of way for a future rail-to-trail conversion on the Craven ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to buy according to Billionaire Ken Fisher. Ken Fisher is a prominent ...

Eli Lilly and Novo Nordisk didn't quite beat expectations with their recent earnings. Their weight loss drugs slightly underperformed. That underperformance may portend more difficulty.

Eli Lilly's weight loss drug sales in Q3 weren't as strong as it anticipated. Its earnings will continue to grow at a rapid pace regardless. It still has a couple of levers it can pull to drive ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low volatility stocks. We will also discuss the latest updates around the market and ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...